ICUI
Market read
The latest filing is mixed. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
Invalidation: The isolated read changes if ICUI's group or a disclosed connection begins moving with it.
Research brief
The latest filing is mixed. 0 of 1 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 6 directly disclosed connections are confirming.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“44 Table of Contents The interest expense component decreased for the three and six months ended June 30, 2026, as compared to the respective prior year periods, primarily due to lower obligation principal balances resulting from principal prepayments includi…”10-Q · Aug 6, 2026 ↗
“Based on current geopolitical conditions we expect foreign currency exchange rates, freight costs, oil prices, interest rates, and general inflation to remain subject to volatility in the market.”10-Q · Aug 6, 2026 ↗
“These favorable impacts were partially offset by a 1.3% unfavorable impact from tariff expense and the impact of foreign currency exchange rate changes.”10-Q · Aug 6, 2026 ↗
“Based on current geopolitical conditions we expect foreign currency exchange rates, freight costs, oil prices, interest rates, and general inflation to remain subject to volatility in the market.”10-Q · Aug 6, 2026 ↗
Valuation discipline
Price/sales 1.8× · EV/sales 2.3×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 10 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for ICUI. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment
10-Q filed 2026-08-06 against the comparable filing from 2025-08-07.
Capital and cash conversion
Capital-spending intensity declined while free-cash-flow margin improved.
Capex, revenue, and operating cash flow are matched to the same reported duration. Reported accounting context, not a forecast or trading recommendation.
“Infusion Systems The following table summarizes our total Infusion Systems revenue (in millions, except percentages): Three months ended June 30, Six months ended June 30, 2026 2025 $ Change % Change 2026 2025 $ Change % Change Infusion Systems (GAAP) $ 189.0 $ 167.7 $ 21.3 12.7 % $ 368.6 $ 334.0 $ 34.6 10.4 % Impact of foreign currency exchange rate changes (0.9) (4.6) Infusion Systems on a constant currency basis (non-GAAP) $ 188.1 $ 364.0 $ Change in constant currency $ 20.4 $ 30.0 % Change in constant currency 12.2 % 9.0 % Infusion Systems revenue increased for the three and six months ended June 30, 2026, as compared to the same periods in the prior year, primarily driven by approximat...”
“The increase in gross margin for the three months ended June 30, 2026, as compared to the same period in the prior year, was primarily driven by (i) 18.9 million or 3.4% impact from tariff refunds that were received during the second quarter of 2026 and (ii) approximately a 1.7% impact from the May 1, 2025 sale of a 60% interest in our lower margin IV Solutions business.”
“The increase in gross margin for the six months ended June 30, 2026, as compared to the same period in the prior year, was primarily driven by (i) 18.9 million or 1.7% impact from tariff refunds that were received during the second quarter of 2026 and (ii) approximately a 3.4% impact from the May 1, 2025 sale of a 60% interest in our lower margin IV Solutions business.”
Historical filing backfill generated after the original filing window. It is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“We compete with products and systems marketed by Becton Dickinson ("BD"), Baxter International ("Baxter"), B.”
“We compete with products and systems marketed by Becton Dickinson ("BD"), Baxter International ("Baxter"), B.”
Depended on by
“To administer Treprostinil Injection through subcutaneous injection, patients currently must use the CADD-MS 3 infusion pump manufactured by ICU Medical.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
ICUI is currently a Leader in the organic co-movement group Infusion & Vascular Access. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for ICUI; it is not active in the latest market snapshot.
Context history
No durable theme membership has been observed for this name yet.